AstraZeneca moves severe asthma drug into final-stage trials
LONDON Oct 30 (Reuters) - AstraZeneca said on Wednesday it was advancing its experimental biotech drug benralizumab into final-stage clinical trials for severe uncontrolled asthma.
The start of the Phase III study programme for the medicine, which was in-licensed from Kyowa Hakko Kirin, bolsters the British drugmaker's thin late-stage pipeline.
AstraZeneca badly needs to reinvigorate its pipeline to offset the impact of a raft of patent expiries on existing drugs that are dragging down sales and profits. The company will report third-quarter results on Thursday.
- North Korea's 'reign of terror' worries South's leader
- Los Angeles sheriff's officials charged in jail misconduct probe
- Google bus blocked in San Francisco gentrification protest
- Putin dissolves state news agency, tightens grip on Russia media
- South Carolina sheriff refuses to lower flag for Mandela